Herbert Irving Comprehensive Cancer Center
Flash Section
HICCC

Welcome to the Cancer Center's clinical trials online search tool. Clinical trials are studies designed to test the effectiveness of new treatments, including new drugs or new combinations of drugs.

Advanced Search Form


8 Results

Cervix, Colon, Lung, Mesothelioma, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Bladder

ID:AAAQ7429

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors


For more information about this trial, please call 646-317-0540

Anus, Bones and Joints, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Ill-Defined Sites, Kaposis sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Melanoma, skin, Mesothelioma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAQ8124

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-6041

Anus, Bones and Joints, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mesothelioma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Bladder

ID:AAAP2403

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-6041

Breast - Female, Breast - Male, Colon, Kidney, Lung, Melanoma, skin, Mesothelioma, Pancreas, Soft Tissue

ID:AAAO1854

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors

This study is being done to determine how patients with advanced or refractory solid tumors (cancer that continues to grow in spite of receiving standard treatment) respond to increasing doses of an investigational drug, CB-839, to determine the dose of CB-839 that can be given without causing severe side effects and to look for early signs of clinical activity. CB-839 blocks the production of glutamate which is critical for tumor cell growth. Investigational means that has not been approved by the United States Food and Drug Administration (FDA) for use outside of research studies. This study will also determine the effect of the study drug by analyzing biomarkers. Biomarkers are substances in your body that can be used to detect a disease or to find out how the cancer is responding to treatment. In this study, biomarkers found in tumor tissue and blood will be collected and tested to see if the study drug causes changes in the way the cancer behaves. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at (646) 317-6041

Anus, Bones and Joints, Breast - Female, Breast - Male, Colon, Esophagus, Eye and Orbit, Ill-Defined Sites, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mesothelioma, Other Digestive Organ, Other Endocrine System, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAN9701

Industry
Principal Investigator: Dr. Emerson Lim

Adult: PRO 02/ML28897 MY PATHWAY STUDY: An Open-Label Phase IIA Study Evaluating Trastuzumab/ Pertuzumab, Erlotinib, Vermurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of these Agents

Four different treatment regimens will be evaluated simultaneously in groups of patients who have advanced solid tumors that has progressed following administration of standard of care treatment, or for whom no standard therapy exists, or for whom therapies that will convey clinical benefit are not available, and in whom a trial of targeted therapy is considered the best available treatment option.1. Erlotinib is a targeted drug that blocks the activity of epidermal growth factor receptor (EGFR), a protein found in increased amounts in certain cancers. EGFR, when overactive, leads to abnormal cell growth. By blocking the activity of EGFR, erlotinib works to help stop this abnormal growth.2. Trastuzumab and pertuzumab are drugs that target the HER2 receptor, a protein found in high quantities in HER2-positive cancers. Pertuzumab is believed to work in a way that is complementary to trastuzumab, as the two medicines target different regions on the HER2 receptor.3. Vemurafenib is a targeted drug that inhibits BRAF kinase, a protein found in certain cancers. BRAF kinase causes abnormal cell growth. By blocking the activity of the BRAF kinase, vemurafenib stops this abnormal growth. The presence of abnormal BRAF kinase in cancer cells can be detected by finding a mutation in the BRAF gene within the cancer.4. Vismodegib is a targeted drug that inhibits the hedgehog pathway in cancer cells. When overactive, the hedgehog pathway plays an important role in the cell’s ability to grow and multiply as a cancer cell. By blocking the hedgehog pathway, vismodegib can stop this abnormal growth. The hedgehog pathway is known to be overactive in cancers with mutations in the genes responsible for this pathway. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Emerson Lim at (212) 305- 0170

Anus, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Ill-Defined Sites, Kaposis sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Mesothelioma, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAP0559

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies

The purpose of this research study is to find the highest safe dose of the drug MGCD265 that can be given to participants with advanced cancer. The safety of this drug, and the effect that it has on the particpants disease and your body will also be studied. MGCD265 is a drug that works by blocking proteins that are important for cancer cells to grow. MGCD265 also prevents the growth of new blood vessels that help cancer tumors grow and spread. MGCD265 an investigational agent. This means that MGCD265 is not approved by the Food and Drug Administration (FDA). Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-6041

Breast - Female, Cervix, Colon, Esophagus, Lip, Oral Cavity and Pharynx, Mesothelioma, Soft Tissue, Stomach, Thyroid

ID:AAAP4558

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMORS

The purpose of this study is to find out what effects, good or bad, MPDL3280A has on advanced solid tumors. This is a phase II study to test the effectiveness of the drug as a potential treatment option for people with cancer.MPDL3280A is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the PD-L1 pathway. The PD-L1 pathway is involved in regulating the body’s natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD-L1 pathway, MPDL3280A may help your immune system stop or reverse the growth of tumors. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Naiyer Rizvi at (646) 317 6344

Anus, Bones and Joints, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Ill-Defined Sites, Kaposis sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mesothelioma, Mycosis Fungoides, Non-Hodgkins Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAQ4758

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY 1251152 in patients with advanced cancer

The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-6041

bottom